Psyence Biomedical Ltd.

Biotechnology • Healthcare • Toronto, ON, United States • PBMWW (NCM)

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

416 346 7764 121 Richmond Street West, Toronto, ON M5H2K1, Canada

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Psyence Biomedical stock rises after ethics approval for psilocybin trial - Investing.com

Investing.com • Dec 19

Psyence Biomedical Stock Prediction: 2024 Outlook & Potential - shababeek.org

shababeek.org • Jan 2

Psyence BioMed (Nasdaq: PBM) advances Phase IIb trial, ibogaine supply leadership - Stock Titan

Stock Titan • Dec 9

Psyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine Production - Yahoo Finance

Yahoo Finance • Sep 2

Rapid Surge: Psyence Biomedical’s Unexpected Stock Movement - StocksToTrade

StocksToTrade • Dec 9

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has PSYENCE BIOMEDICAL LTD. had layoffs?

No layoff events have been recorded for PSYENCE BIOMEDICAL LTD. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does PSYENCE BIOMEDICAL LTD. have?

PSYENCE BIOMEDICAL LTD. has approximately 12 employees.

What industry is PSYENCE BIOMEDICAL LTD. in?

PSYENCE BIOMEDICAL LTD. operates in the Biotechnology industry, within the Healthcare sector.

Is PSYENCE BIOMEDICAL LTD. a publicly traded company?

Yes, PSYENCE BIOMEDICAL LTD. is publicly traded under the ticker symbol PBMWW on the NCM.

Where is PSYENCE BIOMEDICAL LTD. headquartered?

PSYENCE BIOMEDICAL LTD. is headquartered in Toronto, ON, United States at 121 Richmond Street West, Toronto, ON M5H2K1, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.